文献速递妇科

终身癌症风险与复方口服避孕药:皇家全科医师学院口服避孕研究

Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study.
PubMed 文献 · Am J Obstet Gynecol · 2017-02-08

该研究对1968至1969年招募的46022名女性随访至多44年,发现曾用复方口服避孕药者结直肠癌、子宫内膜癌、卵巢癌及淋巴与造血系统癌症风险降低,肺癌风险仅在招募时吸烟的曾用者中升高。当前或近期使用者的乳腺癌和宫颈癌风险在停药约5年内消失,曾用者晚年无新发癌症风险,总体癌症风险平衡为中性。

要点

  • 曾用复方口服避孕药与结直肠癌、子宫内膜癌、卵巢癌及淋巴与造血系统癌症风险降低相关。
  • 当前或近期使用者的乳腺癌和宫颈癌风险在停药约5年内消失,曾用者无随时间升高的风险。
  • 曾用者总体癌症风险平衡为中性,保护效应至少持续30年。

核心结论

  • 多数选择使用口服避孕药的女性不暴露于长期癌症危害,部分癌症风险降低在停药后持续多年。

研究设计与样本

  • 研究为对1968年和1969年招募至皇家全科医师学院口服避孕研究的46022名女性进行至多44年观察。
  • 计算曾用者和从未用者的直接标准化癌症发生率,并按年龄、产次、社会阶层和吸烟进行标准化。
  • 使用泊松回归估计曾用者与从未用者之间的发病率比,并检查末次口服避孕药使用后的时间效应。

主要发现

  • 曾用者中有4661人在884895女性年观察中至少发生1次癌症,从未用者中有2341人在388505女性年观察中至少发生1次癌症。
  • 曾用口服避孕药与结直肠癌(发病率比0.81;99%置信区间0.66-0.99)、子宫内膜癌(发病率比0.66;99%置信区间0.48-0.89)、卵巢癌(发病率比0.67;99%置信区间0.50-0.89)及淋巴与造血系统癌症(发病率比0.74;99%置信区间0.58-0.94)风险降低相关。
  • 肺癌风险升高仅见于招募时吸烟的曾用者。
  • 当前和近期使用者中观察到的乳腺癌和宫颈癌风险升高在停止口服避孕药约5年内似乎消失,曾用者中无证据显示这两种癌症风险随时间升高。
  • 无证据显示曾用口服避孕药的女性晚年出现新的癌症风险。

关键数值与推荐

  • 曾用者结直肠癌发病率比0.81(99%置信区间0.66-0.99)。
  • 曾用者子宫内膜癌发病率比0.66(99%置信区间0.48-0.89)。
  • 曾用者卵巢癌发病率比0.67(99%置信区间0.50-0.89)。
  • 曾用者淋巴与造血系统癌症发病率比0.74(99%置信区间0.58-0.94)。
  • 曾用者总体癌症风险平衡为中性,风险升高被子宫内膜癌、卵巢癌和结直肠癌的获益所抵消,这些获益至少持续30年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral contraceptives have been used by hundreds of millions of women around the world. Important questions remain regarding the very long-term cancer risks that are associated with oral contraception. Despite previous research, important questions remain about the safety of these contraceptives: (1) How long do endometrial, ovarian, and colorectal cancer benefits persist? (2) Does combined oral contraceptive use during the reproductive years produce new cancer risks later in life? (3) What is the overall balance of cancer among past users as they enter the later stages of their lives? OBJECTIVES: The purpose of this study was to examine the very long-term cancer risks or benefits associated with the use of combined oral contraceptives, including the estimated overall life-time balance. STUDY DESIGN: The 46,022 women who were recruited to the UK Royal College of General Practitioners' Oral Contraception Study in 1968 and 1969 were observed for up to 44 years. Directly standardized rates of specific and any cancer were calculated for "ever" and "never" users of combined oral contraceptives; data were standardized for age, parity, social class, and smoking. Attributable risk and preventive fraction percentages were calculated. Poisson regression that adjusted for the same variables was used to estimate incidence rate ratios between ever and never users and to examine effects by time since last oral contraceptive use. RESULTS: There were 4661 ever users with at least 1 cancer during 884,895 woman-years of observation and 2341 never users with at least 1 cancer during 388,505 woman-years of observation. Ever use of oral contraceptives was associated with reduced colorectal (incidence rate ratio, 0.81; 99% confidence interval, 0.66-0.99), endometrial (incidence rate ratio, 0.66; 99% confidence interval, 0.48-0.89), ovarian (incidence rate ratio, 0.67; 99% confidence interval, 0.50-0.89), and lymphatic and hematopoietic cancer (incidence rate ratio, 0.74; 99% confidence interval, 0.58-0.94). An increased risk of lung cancer was seen only among ever users who smoked at recruitment. An increased risk of breast and cervical cancer that was seen in current and recent users appeared to be lost within approximately 5 years of stopping oral contraception, with no evidence of either cancer recurring at increased risk in ever users with time. There was no evidence of new cancer risks appearing later in life among women who had used oral contraceptives. Thus, the overall balance of cancer risk among past users of oral contraceptives was neutral with the increased risks counterbalanced by the endometrial, ovarian, and colorectal cancer benefits that persist at least 30 years. CONCLUSION: Most women who choose to use oral contraceptives do not expose themselves to long-term cancer harms; instead, with some cancers, many women benefit from important reductions of risk that persist for many years after stopping.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol. 2017. PMID: 28188769. doi:10.1016/j.ajog.2017.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。